Karo Healthcare Revenue and Competitors
Estimated Revenue & Valuation
- Karo Healthcare's estimated annual revenue is currently $104.9M per year.
- Karo Healthcare's estimated revenue per employee is $201,000
Employee Data
- Karo Healthcare has 522 Employees.
- Karo Healthcare grew their employee count by 4% last year.
Karo Healthcare's People
Name | Title | Email/Phone |
---|---|---|
1 | Director - Digital Marketing & Media | Reveal Email/Phone |
2 | Marketing Manager UK&I | Reveal Email/Phone |
Karo Healthcare Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $17.1M | 85 | -21% | N/A | N/A |
#2 | $99.7M | 496 | 22% | N/A | N/A |
#3 | $22.9M | 114 | -67% | N/A | N/A |
#4 | $27.3M | 136 | 7% | N/A | N/A |
#5 | $20.9M | 104 | 28% | N/A | N/A |
#6 | $103.1M | 513 | 4% | N/A | N/A |
#7 | $9.4M | 47 | 2% | N/A | N/A |
#8 | $2.4M | 12 | -20% | N/A | N/A |
#9 | $28.1M | 140 | 27% | N/A | N/A |
#10 | $5M | 25 | 4% | N/A | N/A |
What Is Karo Healthcare?
Karo Healthcare delivers smart choices for everyday healthcare. We own and commercialise branded, original over-the-counter products and prescription medicines across a range of everyday categories, including intimate health; skin health; digestive health, foot health; pain, cough and cold; wellness; and specialty products. Our products are available in more than 90 countries and sold through pharmacies, retailers and via healthcare providers. We have our own sales organisation in more than 10 European countries, with the Nordic region as our core market. Karo Healthcare is headquartered in Stockholm, Sweden, and owned by EQT Partners since 2019.
keywords:N/AN/A
Total Funding
522
Number of Employees
$104.9M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $215.6M | 534 | -1% | N/A |
#2 | $75M | 534 | 1% | N/A |
#3 | $97.7M | 558 | 18% | N/A |
#4 | $72.2M | 566 | N/A | N/A |
#5 | $103.1M | 569 | 10% | N/A |